Evidence map›Paper›PMID 42277918›Full record

ArticleOrphanet journal of rare diseases2026

Behavioral and emotional symptoms and quality of life in a national sample of individuals with CLN3 Batten disease.

Beate Oerbeck, Ingrid B Helland, Heather R Adams, Kristin Romvig Overgaard

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Beate OerbeckDivision of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0003-1468-8339
Ingrid B Helland *Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-2575-3573
Heather R AdamsDepartments of Neurology & Pediatrics, University of Rochester Medical Center, Rochester, New York, USA.ORCID http://orcid.org/0000-0002-5992-4297
Kristin Romvig Overgaard *Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. k.r.overgaard@medisin.uio.no.ORCID http://orcid.org/0000-0002-8150-9030

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCLN3 Batten disease, also known as Juvenile Neuronal Ceroid Lipofuscinosis, is a childhood-onset neurodegenerative disorder caused by mutations in the CLN3 gene, frequently accompanied by emotional and behavioral symptoms. Although these symptoms and a reduced quality of life have been previously reported in individuals with CLN3 disease and their parents, no published comparisons with siblings exist. Furthermore, age and sex differences require further study. In a nationally representative sample (n = 20, age 7-29 years), the present study applied the ASEBA Behavior Checklists, the Inventory of Life Quality to examine the prevalence of emotional and behavioral problems and quality of life in affected individuals and sibling controls. Additionally, we assessed parental quality of life using the Satisfaction With Life Scale.

resultsWe found that individuals with CLN3 disease scored in the borderline clinical range for the ASEBA total problem scores (mean 63.1, SD 11.6), whereas siblings fell within the normal variation range (mean 46.4, SD 11.4). A severely reduced quality of life was reported for both affected individuals and their parents, while siblings scored within the normal range. No significant sex differences were found. Despite facing significant challenges, families also reported strengths in their offspring: grit, determination and a sense of humor in affected individuals, and empathy and dutifulness in sibling controls.

conclusionsThis study underscores the significant emotional and behavioral challenges faced by individuals with CLN3 Batten disease, which affect the quality of life for them and their parents. These findings emphasize the need for targeted interventions for both the patients and their families.

Indexed as

Neuronal Ceroid-LipofuscinosesAdolescentAdultChildEmotionsFemaleHumansMaleMembrane GlycoproteinsMolecular ChaperonesQuality of LifeSiblingsYoung AdultCLN3 protein, humanMembrane GlycoproteinsMolecular ChaperonesABCLCBCLJuvenile neuronal ceroid lipofuscinosisSpielmeyer-Vogt disease

Identifiers

PMID42277918
PMCPMC13487928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.